Magentiq-Eye Ltd. received U.S. FDA 510(k) clearance for its Magentiq-Colo, an artificial intelligence (AI) gastrointestinal software system that helps detect lesions in real time during colonoscopy procedures. With the rate of colorectal cancer expected to increase steadily through the decade, the company hopes that Magentiq-Colo will offer the gastroenterology community and its patients a significant increase in the adenoma detection rate.
The gastroenterology team at the Paoli-Calmettes Institute in Marseille, France is conducting a therapeutic trial using G-Eye, the latest generation of colonoscope from Hanofar, Israel-based Smart Medical Systems Ltd. “The aim is to increase the detection rate of polyps thanks to a new type of device that can be connected to the current colonoscopes on the market,” Jean-Philippe Ratone, the principal investigator of the study and gastroenterologist at the Paoli-Calmettes Institute told BioWorld.
Smart Medical Systems Ltd. has released positive data showing its FDA-cleared G-eye balloon endoscope has a higher adenoma detection rate (ADR) compared to Olympus’ Endocuff Vision (ECV) technology in patients undergoing screening or surveillance colonoscopy.
